Akebia Therapeutics (AKBA) stock is up more than 17% Tuesday and is higher by 23.3% this week. AKBA stock has fallen -34.6% over the last 12 months, and the average rating from Wall Street analysts is a Moderate Buy. Stock Score Report, InvestorsObserver’s proprietary scoring system, gives AKBA stock a score of 52 out of a possible 100.
That score is mainly influenced by a fundamental score of 73. In addition to the average rating from Wall Street analysts, AKBA stock has a mean target price of $15.00. This means analysts expect the stock to gain 198.80% over the next 12 months. AKBA’s score also includes a short-term technical score of 42. The long-term technical score for AKBA is 42.
What’s Happening with AKBA Stock Today
Akebia Therapeutics Inc (AKBA) stock has gained 17.39% while the S&P 500 has fallen -0.43% as of 2:26 PM on Tuesday, Sep 10. AKBA is up $0.74 from the previous closing price of $4.28 on volume of 1,021,741 shares. Over the past year the S&P 500 is up 3.07% while AKBA has fallen -34.55%. AKBA lost -$2.43 per share in the over the last 12 months.